Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

100.83 -0.56 (-0.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Blueprint Medicines Corp

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
Blueprint Medicines's Earnings: A Preview
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
What 15 Analyst Ratings Have To Say About Blueprint Medicines
Via Benzinga
Blueprint Medicines Corp. (NASDAQ: BPMC) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Unpacking Blueprint Medicines' Ayvakit's Bright Future: Insights From Latest Physician Survey On Sales Predictions
Needham slightly increased the price target for Blueprint Medicines Corp (NASDAQ: BPMC) from $65 to $66  
Via Benzinga
Why Shares of Blueprint Medicines Are Falling Wednesday
The company had generally improved earnings. 
Via The Motley Fool
A Preview Of Blueprint Medicines's Earnings
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
What Will AbbVie Buy Next?
Two mid-cap drugmakers stand out as logical targets for AbbVie. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
3 Biotech Stocks Using AI to Change Healthcare Forever
These three biotech firms are leveraging artificial intelligence to revolutionize therapeutics and make disease a thing of the past. 
Via InvestorPlace
Analyst Expectations for Blueprint Medicines's Future
Via Benzinga
FDA OKs Blueprint Medicines' Blood Disorder Drug As First Treatment For SM Patients
The U.S. 
Via Benzinga
Analyst Expectations for Blueprint Medicines's Future
Via Benzinga
Blueprint Medicines's Return On Capital Employed Overview
Via Benzinga
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
Via Talk Markets
ETF Returns: Mid-Cap Winners And Losers
We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on... 
Via Benzinga
3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon
These three small cap drug companies could become gold or lead depending on the outcomes of their clinical trials. 
Via InvestorPlace
EPAM Systems, Amyris, Blueprint Medicines And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Dow Jones dropping around 100 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 5, 2023
Via Benzinga
US Stocks Mixed; SAIC Posts Upbeat Results
U.S. stocks traded mixed this morning, with Dow Jones dropping around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.06% to 33,740.98 while the NASDAQ rose 0.08% to... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Meta Platforms To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Monday
BMO Capital boosted the price target for Equity Residential (NYSE: EQR) from $60 to $64. BMO Capital analyst John Kim upgraded the stock from Underperform to Market Perform. Equity Residential shares... 
Via Benzinga
This Biotech Could Soon Go Parabolic, But Should You Buy It?
Its situation is neither as good nor as bad as it might seem at first glance. 
Via The Motley Fool
Blueprint Medicines Earns Higher Price Targets Post FDA Approval: Analysts Optimistic on Ayvakit's Future
Shares of Blueprint Medicines Corporation (NASDAQ: BPMC) after it received FDA approval for its Ayvakit (avapritinib) as the first, only treatment for  
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.